Preoperative chemoradiotherapy in esophageal cancer
Oncología (Barcelona) · 2004
DOI: 10.4321/s0378-48352004000400004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncología (Barcelona), 2004. Verfasst von T. Conroy.
Abstract (Originalsprache)
Esophageal cancer is a challenging clinical problem.Despite surgical advances and use of combined-modality approaches, the prognosis remains dismal.According to the EU-ROCARE-3 study (1990-1994), the overall European 1-year and 5-year relative survival rates were 33% and 10%, respectively 1 and a plateau in survival following single modality treatment has been reached. Natural history of esophageal cancerEsophageal cancers have extensive local growth and early lymph node involvement before widespread dissemination.Interconnexions between lymphatic channels of the esophagus provide a submucous passway for the lymphatic dissemination of cancer.Viable tumor emboli can be found sometimes as much as 8 cm distant from the primary cancer.The disease causes death by both local growth and distant metastases [2][3][4][5][6] .Lymph node involvement is documented in 61-74% of patients.Distant metastases have been noted in virtually every tissue, including lymph nodes, lungs, liver, adrenals, stomach, bones and kidneys.
Zitieren
APA
Conroy, T. (2004). Preoperative chemoradiotherapy in esophageal cancer. Oncología (Barcelona). https://doi.org/10.4321/s0378-48352004000400004
Vancouver
Conroy T. Preoperative chemoradiotherapy in esophageal cancer. Oncología (Barcelona). 2004. doi:10.4321/s0378-48352004000400004
BibTeX
@article{Conroy2004,
author = {Conroy, T.},
title = {Preoperative chemoradiotherapy in esophageal cancer},
journal = {Oncología (Barcelona)},
year = {2004},
doi = {10.4321/s0378-48352004000400004}
}
EUVIMED